Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
---|---|---|---|---|---|---|
SC 13G | 2024-03-29 | Carlyle Group Inc. | Q32 Bio Inc. | 1,102,741 | 9.2% | EDGAR |
SC 13D/A | 2024-03-05 | Carlyle Group Management L.L.C. | Carlyle Group Inc. | 140,827,506 | 39.0% | EDGAR |
SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Carlyle Group Inc. | 24,876,188 | 6.9% | EDGAR |
SC 13D/A | 2024-02-12 | Carlyle Group Inc. | Jasper Therapeutics, Inc. | 1,066,189 | 7.1% | EDGAR |
SC 13G/A | 2024-02-12 | MORGAN STANLEY | Carlyle Group Inc. | 10,485,962 | 2.9% | EDGAR |
SC 13G/A | 2024-02-12 | Carlyle Group Inc. | HilleVax, Inc. | 1,838,486 | 3.8% | EDGAR |
SC 13G/A | 2024-02-12 | Carlyle Group Inc. | Phathom Pharmaceuticals, Inc. | 3,496,808 | 6.1% | EDGAR |
SC 13G/A | 2024-02-12 | Carlyle Group Inc. | MKS INSTRUMENTS INC | 0 | 0.0% | EDGAR |
SC 13G/A | 2024-02-12 | Carlyle Group Inc. | ZoomInfo Technologies Inc. | 35,244,474 | 9.0% | EDGAR |
SC 13G | 2024-02-09 | Capital World Investors | Carlyle Group Inc. | 20,008,088 | 5.5% | EDGAR |
SC 13D/A | 2024-02-07 | Carlyle Group Inc. | Adicet Bio, Inc. | 3,060,292 | 4.1% | EDGAR |
SC 13G | 2024-01-25 | BlackRock Inc. | Carlyle Group Inc. | 31,155,048 | 8.6% | EDGAR |
SC 13D/A | 2024-01-03 | Carlyle Group Inc. | CommScope Holding Company, Inc. | 42,257,593 | 16.6% | EDGAR |
SC 13D/A | 2023-10-16 | Carlyle Group Inc. | SOLENO THERAPEUTICS INC | 2,893,615 | 10.0% | EDGAR |
SC 13D/A | 2023-10-03 | Carlyle Group Inc. | SOLENO THERAPEUTICS INC | 1,567,247 | 10.0% | EDGAR |
SC 13G | 2023-09-22 | Carlyle Group Inc. | Complete Solaria, Inc. | 2,745,879 | 5.7% | EDGAR |
SC 13D/A | 2023-09-14 | Carlyle Group Inc. | Carlyle Credit Income Fund | 4,785,628 | 41.0% | EDGAR |
SC 13D/A | 2023-08-30 | Carlyle Group Inc. | Carlyle Credit Income Fund | 3,516,091 | 33.8% | EDGAR |
SC 13D/A | 2023-08-18 | Carlyle Group Inc. | SOLENO THERAPEUTICS INC | 1,227,317 | 12.3% | EDGAR |
SC 13D/A | 2023-08-18 | Carlyle Group Inc. | eFFECTOR Therapeutics, Inc. | 4,829,891 | 7.8% | EDGAR |